Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians.
about
Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiencyCooperation between pathologists and clinicians allows a better diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms.Imatinib and ruxolitinib association: first experience in two patients.Ruxolitinib in Myelofibrosis and Polycythemia Vera.The Relative Bioavailability, Food Effect, and Drug Interaction With Omeprazole of Momelotinib Tablet Formulation in Healthy Subjects.
P2860
Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Ruxolitinib: a potent and sele ...... sis. An update for clinicians.
@en
type
label
Ruxolitinib: a potent and sele ...... sis. An update for clinicians.
@en
prefLabel
Ruxolitinib: a potent and sele ...... sis. An update for clinicians.
@en
P2860
P356
P1476
Ruxolitinib: a potent and sele ...... sis. An update for clinicians.
@en
P2093
Alessandro M Vannucchi
Claire Harrison
P2860
P304
P356
10.1177/2040620712459746
P577
2012-12-01T00:00:00Z